DE69812410D1 - Verwendung von 5ht1a rezeptor antagonisten zur vorbeugung und/oder behandlung von epilepsie - Google Patents

Verwendung von 5ht1a rezeptor antagonisten zur vorbeugung und/oder behandlung von epilepsie

Info

Publication number
DE69812410D1
DE69812410D1 DE69812410T DE69812410T DE69812410D1 DE 69812410 D1 DE69812410 D1 DE 69812410D1 DE 69812410 T DE69812410 T DE 69812410T DE 69812410 T DE69812410 T DE 69812410T DE 69812410 D1 DE69812410 D1 DE 69812410D1
Authority
DE
Germany
Prior art keywords
preventing
receptor antagonists
treating epilepsy
5ht1a receptor
5ht1a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69812410T
Other languages
English (en)
Other versions
DE69812410T2 (de
Inventor
L Jacobs
Elizabeth Gould
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Application granted granted Critical
Publication of DE69812410D1 publication Critical patent/DE69812410D1/de
Publication of DE69812410T2 publication Critical patent/DE69812410T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69812410T 1997-12-05 1998-12-04 Verwendung von 5ht1a rezeptor antagonisten zur vorbeugung und/oder behandlung von epilepsie Expired - Fee Related DE69812410T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US985766 1997-12-05
US08/985,766 US5919802A (en) 1997-12-05 1997-12-05 Methods of preventing and/or treating temporal lobe epilepsy
PCT/US1998/025745 WO1999029323A1 (en) 1997-12-05 1998-12-04 Use of 5ht1a receptor antagonists for preventing and/or treating temporal lobe epilepsy

Publications (2)

Publication Number Publication Date
DE69812410D1 true DE69812410D1 (de) 2003-04-24
DE69812410T2 DE69812410T2 (de) 2004-04-01

Family

ID=25531770

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69812410T Expired - Fee Related DE69812410T2 (de) 1997-12-05 1998-12-04 Verwendung von 5ht1a rezeptor antagonisten zur vorbeugung und/oder behandlung von epilepsie

Country Status (11)

Country Link
US (1) US5919802A (de)
EP (1) EP1037637B1 (de)
JP (1) JP2001525368A (de)
AT (1) ATE234618T1 (de)
AU (1) AU738121B2 (de)
CA (1) CA2312760A1 (de)
DE (1) DE69812410T2 (de)
DK (1) DK1037637T3 (de)
ES (1) ES2194378T3 (de)
PT (1) PT1037637E (de)
WO (1) WO1999029323A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9906220A (pt) * 1999-12-17 2001-06-26 Luiz Eugenio Araujo De M Mello Uso de sais de escopolamina
GB0515090D0 (en) * 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
JP2012133453A (ja) 2010-12-20 2012-07-12 Sony Corp 情報処理装置、情報処理方法及びプログラム
CN108057032B (zh) * 2018-01-30 2020-06-05 中国人民解放军第二军医大学第二附属医院 阿尔维林在制备预防或治疗门脉高压症的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US587593A (en) * 1897-08-03 Owen moran
WO1993000313A2 (en) * 1991-06-27 1993-01-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
ZA929008B (en) * 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
WO1993013766A1 (en) * 1992-01-07 1993-07-22 Merrell Dow Pharmaceuticals Inc. Treatment of involuntary movements with 5ht1a receptor agonists
FR2722194B1 (fr) * 1994-07-06 1996-08-23 Adir Nouveaux derives de benzopyrane, leur procede de preparation et les compositions pharmacuetiques qui les contiennent
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
GB9419024D0 (en) * 1994-09-21 1994-11-09 Wyeth John & Brother Ltd Bicyclic carboxamides

Also Published As

Publication number Publication date
ATE234618T1 (de) 2003-04-15
EP1037637A1 (de) 2000-09-27
AU1626099A (en) 1999-06-28
PT1037637E (pt) 2003-07-31
DK1037637T3 (da) 2003-06-23
AU738121B2 (en) 2001-09-06
US5919802A (en) 1999-07-06
ES2194378T3 (es) 2003-11-16
DE69812410T2 (de) 2004-04-01
EP1037637B1 (de) 2003-03-19
JP2001525368A (ja) 2001-12-11
CA2312760A1 (en) 1999-06-17
WO1999029323A1 (en) 1999-06-17

Similar Documents

Publication Publication Date Title
ATE403437T1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69617235D1 (de) Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ATE154758T1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
DE69637587D1 (de) Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE69812410D1 (de) Verwendung von 5ht1a rezeptor antagonisten zur vorbeugung und/oder behandlung von epilepsie
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE60004473D1 (de) Verwendung von gaba-b rezeptor liganden zur herstellungen von medikamenten zur behandlung von neurodegenerativen erkrankungen
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee